Short-Term Outcomes of TAVR in Asymptomatic or Minimally Symptomatic Patients

Aortic valve replacement (AVR) is indicated for symptomatic aortic stenosis (AS), while close follow-up is recommended for asymptomatic patients, unless they have elevated aortic gradients, low ejection fraction, or abnormal stress tests. However, the optimal timing to perform AVR is uncertain, especially with recent evidence suggesting that patients with AS associated with signs of myocardial damage have higher long-term mortality and worse outcomes, even in the absence of symptoms.

TAVI en insuficiencia aórtica pura

Currently, the procedural risk and the recovery after transcatheter aortic valve replacement (TAVR) are more favorable compared with surgery. Similarly, more information is needed on this strategy in asymptomatic or minimally symptomatic patients with severe AS.

The aim of this retrospective study was to assess the outcomes of TAVR in minimally symptomatic patients with severe aortic stenosis.

The primary endpoint (PEP) was a composite of adverse events at 30 days (death, stroke, major bleeding, stage III acute kidney injury, need for dialysis, moderate to severe paravalvular leak).

Read also: Evolución a 10 años del TAVI en pacientes de bajo riesgo.

Among the 231,285 patients with AS treated with TAVR, 20% were minimally symptomatic. Their mean age was 80 years and 47.5% of them were women. The 1-year survival rate was higher for minimally symptomatic patients compared with those with moderate or severe symptoms (hazard ratio [HR] for death: 0.70 [95% confidence interval (CI): 0.66-0.75]). The results of the quality-of-life questionnaire increased by 2.7 points (95% CI: 2.6-2.9) at 30 days and 3.8 points (95% CI: 3.6-4.0) at 1 year in minimally symptomatic patients, compared with increases of 32.2 points (95% CI: 32.0-32.3) at 30 days and 34.9 points (95% CI: 34.7-35.0) at one year in patients with more acute symptoms. Minimally symptomatic patients were more likely to be alive at one year (odds ratio [OR]: 1.19 [95% CI: 1.16-1.23]).

Conclusion

This study showed that patients with minimally symptomatic AS experienced fewer procedural complications and better outcomes at 1 year after TAVR compared with patients with more acute symptoms. Randomized clinical trials are needed to confirm the safety and efficacy of TAVR in minimally symptomatic or asymptomatic patients with AS.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Outcomes of Transcatheter Aortic Valve Replacement in Asymptomatic or Minimally Symptomatic Aortic Stenosis.

Reference: Chetan P. Huded, MD, MSC et al J Am Coll Cardiol Intv 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation

Mitral regurgitation (MR) is a common condition, with approximately 3.5% prevalence in individuals under 65, increasing to 7.7% in those over 75. It can...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...